Catalent has agreed to buy closely held Paragon Bioservices for $1.2B, The Wall Street Journal’s Jared Hopkins and Cara Lombardo report, citing people familiar with the matter. The all-cash deal, which is expected to be announced Monday morning, would help Catalent expand its gene-therapy manufacturing capabilities, sources said. The transaction is expected to close in the second quarter, the publication adds
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.